A higher dose regimen of the IL-23 inhibitor tildrakizumab has potential for reducing disease severity in the longer term for patients with severe hidradenitis suppurativa (HS), experience at one Australian centre suggests. Reporting on the early experience with tildrakizumab in nine patients with severe HS, dermatologists at Royal Melbourne Hospital, said it appeared to be ...
Tildrakizumab shows potential in long-term treatment of severe HS
By Michael Woodhead
23 Mar 2021